A randomized intervention study to evaluate the effect of calcitriol therapy on the renin-angiotensin system in...

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Nephrology

Background:

• Vitamin D therapy may reduce cardiovascular disease (CVD) risk in type 2 diabetes (T2DM) by modulating the renin-angiotensin system (RAS).
• Limited human intervention studies exist on vitamin D receptor (VDR) agonists' effects on RAS activity.

Purpose of the Study:

• To investigate the impact of direct VDR activation using calcitriol on circulating RAS activity.
• To assess calcitriol's effect on vascular hemodynamics in individuals with T2DM.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 18 T2DM participants without chronic kidney disease (CKD).
• Participants received either calcitriol or placebo for three weeks.
• Measured outcomes included plasma renin activity (PRA), aldosterone levels, mean arterial pressure (MAP) response to angiotensin II, and renal plasma flow (RPF).

Main Results:

• Calcitriol administration significantly increased 1,25(OH)2D levels compared to placebo.
• No significant differences were observed in PRA, aldosterone, MAP, or RPF between the calcitriol and placebo groups.
• Vascular hemodynamics and RAS activity remained unchanged despite elevated vitamin D levels.

Conclusions:

• Calcitriol therapy did not significantly alter circulating RAS activity in T2DM patients without CKD.
• Direct VDR activation with calcitriol did not impact vascular hemodynamics in this study cohort.
• These findings suggest calcitriol may not be effective in modifying RAS activity or hemodynamics in T2DM patients without CKD.